Eli Lilly (LLY) Income from Continuing Operations (2009 - 2026)

Eli Lilly has reported Income from Continuing Operations for 18 years, with the latest figure at 7396000000.0 in Q1 2026.

• For the quarter ending Q1 2026, Income from Continuing Operations rose 168.07% year-over-year to 7396000000.0; the trailing twelve-month figure through Mar 2026 stood at 25276700000.0 (up 127.59% YoY), and the FY2025 full-year result was 20640000000.0, up 94.9% from the prior year.
• Income from Continuing Operations for Q1 2026 stood at 7396000000.0, up from 6637700000.0 in the prior quarter.
• The five-year high for Income from Continuing Operations was 7396000000.0 in Q1 2026, with the low at 57400000.0 in Q3 2023.
• Historically, Income from Continuing Operations has averaged 2947676470.59 across 5 years, with a median of 2189300000.0 in 2023.
• Annual changes were most pronounced in 2023 — Income from Continuing Operations sank 103.95% — and 2024, when it surged 1790.42%.
• Eli Lilly's Income from Continuing Operations stood at 1937700000.0 in 2022, then climbed by 12.98% to 2189300000.0 in 2023, then surged by 101.43% to 4409800000.0 in 2024, then jumped by 50.52% to 6637700000.0 in 2025, then increased by 11.42% to 7396000000.0 in 2026.
• The last three Income from Continuing Operations figures came in at 7396000000.0 (Q1 2026), 6637700000.0 (Q4 2025), and 5582500000.0 (Q3 2025), per Business Quant data.